Mammalian target of rapamycin regulates IRS-1 serine phosphorylation.

Drug Week | June 4, 2004 | Copyright

2004 JUN 4 - (NewsRx.com & NewsRx.net) -- A mammalian target of rapamycin regulates insulin receptor substrate (IRS)-1 serine 307 phosphorylation.

According to published research from the United States, "Insulin signaling can be negatively regulated by phosphorylation of serine 307 of the insulin receptor substrate (IRS)-1. Rapamycin, an inhibitor of the kinase mTOR, can prevent serine 307 phosphorylation and the development of insulin resistance. We further investigated the role of mTOR in regulating serine 307 phosphorylation, demonstrating that serine 307 ...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

Rigel Pharmaceuticals' Stockholders Approve Financing and Other Related Proposals at Annual Stockholders' Meeting.
PR Newswire ; Rigel Pharmaceuticals, Inc. announced today that it received...submitted for stockholder vote and identified in Rigel's 2003 proxy statement. Among the proposals receiving approval were Rigel's recently announced financing, a reverse stock...
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update.
PR Newswire ; ...Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today reported...2008. For the third quarter of 2008, Rigel reported a net loss of $37.7 million...in the third quarters of 2008 and 2007. Rigel reported operating expenses of $38.7...
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity.
PR Newswire ; Rigel Program to be Presented at Keystone Scientific...March 27 /PRNewswire-FirstCall/ -- Rigel today announced that Yonchu Jenkins, Ph...Function. Dr. Jenkins and her colleagues at Rigel are investigating ways to inhibit Vif, a...
Rigel Announces 2002 Fiscal Year Financial Results; Company Provides Outlook for 2003 Clinical Progress.
PR Newswire ; ...Calif., Feb. 5 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today reported...with the start of clinical testing for Rigel's first product candidate. Net loss...fiscal 2001. As of December 31, 2002, Rigel had cash, cash equivalents and short...
Rigel Granted Key Patents in Immunology, Virology and Oncology.
PR Newswire ; ...March 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...patents since February 2004. Specifically, Rigel was granted six patents in immunology...Activated Cell Sorter (FACS) technology. Rigel is ranked as one of the top 15 biotech...
Rigel Announces Restructuring To Reduce Spending; Company Cuts Staff While Increasing Focus on Major Drug Development Programs.
PR Newswire ; Rigel Pharmaceuticals announced today that the...As a result of this reduction in force, Rigel will realign its personnel base, predominantly...company's drug development capabilities. Rigel also announced today that, separately from...
Rigel Pharmaceuticals Presents Drug Development Programs in Oncology and Allergy/Inflammation at the Protein Phosphorylation Drug Discovery World Summit; Presentations to Feature Latest Results on Inhibitors of Ubiquitin Ligases and Selected Kinases as Potential Drug Candidates.
PR Newswire ; Rigel Pharmaceuticals, Inc., announced today...for the treatment of cancer. Another of Rigel's programs focuses on a kinase drug target...arthritis," said Donald G. Payan, M.D., Rigel's executive vice president and chief scientific...
Rigel Announces Fourth Quarter and Year End 2007 Financial Results.
PR Newswire ; ...Feb. 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...2007. For the fourth quarter of 2007, Rigel reported a net loss of $19.0 million...million and 25.1 million, respectively. Rigel reported revenue from collaborations of...
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP.
PR Newswire ; ...Nov. 21 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced...T. Participating on the call will be Rigel senior management and the principal investigator...Cornell Medical College. In addition, Rigel will be presenting a poster on R788 in...
Rigel Announces Issuance of HCV and Inflammation Patents; 20 Patents Issued in Last 18 Months.
PR Newswire ; Rigel Pharmaceuticals, Inc. today announced that it...19 other U.S. patents that have been issued to Rigel during the last 18 months. These patents cover core technology useful in Rigel's HCV program, as well as its immunology and...

Find more facts and information related to the article "Mammalian target of rapamycin regulates IRS-1 ..."